Early first-line systemic anticancer therapeutic attrition after metastatic recurrence in triple-negative breast cancer following neoadjuvant chemo-immunotherapy: a multicenter real-world study.

Fedele P, Rizzo A, Landriscina M, Stucci LS, Inneo C, Morritti M, Morelli F, Giuliani F, Moraca L, Cairo G, Giampaglia M, Tedesco B, Melaccio A, Maselli FM, Gnoni A, Licchetta A, Fumai F, Vitale E, Marino FR, Zifarone E, Lanotte L, Ardito R, Gadaleta-Caldarola G

Open source

DOI: 10.1007/s10549-026-08023-2
Published: 2026 Jul 10
Container: Breast cancer research and treatment
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s10549-026-08023-2,
  title = {Early first-line systemic anticancer therapeutic attrition after metastatic recurrence in triple-negative breast cancer following neoadjuvant chemo-immunotherapy: a multicenter real-world study.},
  author = {Fedele P and Rizzo A and Landriscina M and Stucci LS and Inneo C and Morritti M and Morelli F and Giuliani F and Moraca L and Cairo G and Giampaglia M and Tedesco B and Melaccio A and Maselli FM and Gnoni A and Licchetta A and Fumai F and Vitale E and Marino FR and Zifarone E and Lanotte L and Ardito R and Gadaleta-Caldarola G},
  year = {2026},
  journal = {Breast cancer research and treatment},
  doi = {10.1007/s10549-026-08023-2},
  url = {https://doi.org/10.1007/s10549-026-08023-2}
}

RIS

TY  - JOUR
TI  - Early first-line systemic anticancer therapeutic attrition after metastatic recurrence in triple-negative breast cancer following neoadjuvant chemo-immunotherapy: a multicenter real-world study.
AU  - Fedele P
AU  - Rizzo A
AU  - Landriscina M
AU  - Stucci LS
AU  - Inneo C
AU  - Morritti M
AU  - Morelli F
AU  - Giuliani F
AU  - Moraca L
AU  - Cairo G
AU  - Giampaglia M
AU  - Tedesco B
AU  - Melaccio A
AU  - Maselli FM
AU  - Gnoni A
AU  - Licchetta A
AU  - Fumai F
AU  - Vitale E
AU  - Marino FR
AU  - Zifarone E
AU  - Lanotte L
AU  - Ardito R
AU  - Gadaleta-Caldarola G
PY  - 2026
JO  - Breast cancer research and treatment
DO  - 10.1007/s10549-026-08023-2
UR  - https://doi.org/10.1007/s10549-026-08023-2
ER  -

APA

P, F., A, R., M, L., LS, S., C, I., M, M., F, M., F, G., L, M., G, C., M, G., B, T., A, M., FM, M., A, G., A, L., F, F., E, V., FR, M., E, Z., L, L., R, A., & G, G. (2026). Early first-line systemic anticancer therapeutic attrition after metastatic recurrence in triple-negative breast cancer following neoadjuvant chemo-immunotherapy: a multicenter real-world study.. Breast cancer research and treatment. https://doi.org/10.1007/s10549-026-08023-2

Source records

pubmed · retrieved 2026-09-25T01:48:06.213Z